Spectral decomposition of P50 suppression in schizophrenia during concurrent visual processing

1 Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: When do they begin to be effective? Schizophrenia Research, June 18, 2013

2 Practical management of schizophrenia: The role of long-acting Antipsychotics International Clinical Psychopharmacology, May 20, 2013

3 Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials Schizophrenia Bulletin, May 31, 2013

4 The impact of smoking cessation on schizophrenia and major depression Australasian Psychiatry, May 30, 2013    Review Article

5 Quetiapine versus typical antipsychotic medications for schizophrenia Cochrane Reviews, June 12, 2013

6 Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial International Journal of Neuropsychopharmacology, May 23, 2013

7 A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia BMC Psychiatry, May 23, 2013

8 Risperidone long-acting injection in schizophrenia spectrum illnesses compared to first generation depot antipsychotics in an outpatient setting in canada BMC Psychiatry, June 3, 2013
Exclusive Author Commentary

9 Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries Cost Effectiveness and Resource Allocation, June 10, 2013

10 Prenatal vitamin D status and risk of psychotic experiences at age 18years--a longitudinal birth cohort Schizophrenia Research, June 11, 2013